FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Rebel Vivienne I		 2. Date of Event Requiring Statement (MM/DD/YYYY)
8/29/2022 

 3. Issuer Name and Ticker or Trading Symbol

bioAffinity Technologies, Inc. [BIAF]
(Last)        (First)        (Middle)

8922 APACHE TRAIL		 4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                          _____ 10% Owner
___X___ Officer (give title below)        _____ Other (specify below)
EVP, Chief Sci. & Med. Officer /
(Street)

SAN ANTONIO, TX 78255      

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed(MM/DD/YYYY)
 

6. Individual or Joint/Group Filing(Check Applicable Line)

_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		2. Amount of Securities Beneficially Owned
(Instr. 4)		3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock, par value $0.007 (1)7142 D  

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)		2. Date Exercisable and Expiration Date
(MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		4. Conversion or Exercise Price of Derivative Security5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy) (1) (2)7/25/2026 Common Stock 2857 $7.00 D  
Stock Option (right to buy) (1) (3)11/20/2027 Common Stock 2857 $7.70 D  
Stock Option (right to buy) (1) (4)2/25/2029 Common Stock 4285 $7.70 D  
Stock Option (right to buy) (1) (5)2/5/2030 Common Stock 4285 $7.70 D  
Explanation of Responses:
(1) The number of securities and exercise prices reported in this Form 3 reflect the 1-for-7 reverse stock split of the common stock, par value $0.007 (the "Common Stock"), of bioAffinity Technologies, Inc. (the "Issuer"), which became effective with the State of Delaware on June 23, 2022 in connection with the Issuer's initial public offering.
(2) Represents a right to purchase 2,857 shares of Common Stock upon exercise of a ten-year option granted to Dr. Rebel under the Issuer's 2014 Equity Incentive Plan (the "EIP") on July 25, 2016. This option vested in 12 monthly installments beginning on August 25, 2016 and is fully vested and exercisable as of the date of this report.
(3) Represents a right to purchase 2,857 shares of Common Stock upon exercise of a ten-year option granted to Dr. Rebel under the EIP on November 20, 2017. This option vested in 12 monthly installments beginning on December 20, 2017 and is fully vested and exercisable as of the date of this report.
(4) Represents a right to purchase 4,285 shares of Common Stock upon exercise of a ten-year option granted to Dr. Rebel under the EIP on February 25, 2019. This option vested in 12 monthly installments beginning on March 25, 2019 and is fully vested and exercisable as of the date of this report.
(5) Represents a right to purchase 4,285 shares of Common Stock upon exercise of a ten-year option granted to Dr. Rebel under the EIP on February 5, 2020. This option vested in 12 monthly installments beginning on March 5, 2020 and is fully vested and exercisable as of the date of this report.

Remarks:
Exhibit List - Exhibit 24.1: Power of Attorney (Vivienne Rebel)

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Rebel Vivienne I
8922 APACHE TRAIL
SAN ANTONIO, TX 78255

EVP, Chief Sci. & Med. Officer
Signatures
/s/ Wilhelm E. Liebmann, as attorney-in-fact for Vivienne Rebel11/22/2022
**Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
bioAffinity Technologies (NASDAQ:BIAF)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more bioAffinity Technologies Charts.
bioAffinity Technologies (NASDAQ:BIAF)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more bioAffinity Technologies Charts.